SecBot SecBot
SECBOTREPLAY Home › Report › SCYX

SCYX · Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a…

Scynexis · PRESS-RELEASE filed Mar 31, 2026 at 06:40 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 31, 2026 at 06:40 ET

Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant polycystic kidney disease (ADPKD), from Poxel S.A. The deal includes an $8 million upfront payment, $8 million in potential development milestones, and up to $180 million in commercial milestones. SCY-770, a novel AMPK activator with orphan drug designation, is expected to enter a Phase 2 proof-of-concept study in Q4 2026, positioning Scynexis to expand into a high-unmet-need rare disease market.

  • Scynexis acquired SCY-770 (formerly PXL-770) from Poxel S.A. for $8M upfront and up to $196M in total milestones ($8M development + $180M commercial).
  • SCY-770 is a novel, oral, direct AMPK activator with orphan drug designation for ADPKD, a rare genetic kidney disease with limited treatment options.
  • Phase 2 proof-of-concept study in ADPKD patients expected to start in Q4 2026, with early efficacy readout in second half of 2027.
  • Current ADPKD market has only one approved therapy (Jynarque), which had ~$1.5B in U.S. sales in 2024 despite limited uptake.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access